Avience Biomedicals IPO GMP Day 3: GMP Rs 85, 40.9% Listing Premium Expected on NSE SME

Avience Biomedicals IPO GMP Rs 85 (+40.9% premium implied). Price band Rs 196-208. Listing on NSE SME. FY25 revenue Rs 45.97 Cr, PAT Rs 7.23 Cr. Min lot 1200 shares.

The Avience Biomedicals IPO grey market premium has reached Rs 85 on Day 3 of GMP tracking for this NSE SME book-built issue, implying an expected listing price of approximately Rs 293 per share, representing a potential gain of approximately 40.9% over the upper price band of Rs 208. Avience Biomedicals Limited, the Noida-based ISO-certified molecular diagnostics and medical devices manufacturer, is raising Rs 30.24 crore through a 100% fresh issue of 14,53,800 equity shares at a price band of Rs 196 to Rs 208 per share. Kunal Singla, Associate Director at Univest, highlights that the Avience Biomedicals IPO GMP has shown a strong upward trend, rising from Rs 40 in pre-subscription tracking to Rs 70 on Day 1 of subscription and Rs 85 on Day 3 of GMP tracking, reflecting increasing grey market confidence ahead of the final subscription days.

Avience Biomedicals IPO: Key Data Snapshot

Avience Biomedicals IPO GMP Day 3: Why the Rs 85 Premium Is Significant

The Avience Biomedicals IPO GMP of Rs 85 on Day 3 of tracking is notable because it has strengthened progressively: from Rs 40 on the first pre-subscription day, to Rs 70 on subscription Day 1, to Rs 85 on Day 3 of GMP tracking. This rising GMP trajectory contrasts with many SME IPOs where GMP peaks before subscription opens and then moderates. The strengthening GMP suggests increasing grey market demand as subscription data accumulates. The Avience Biomedicals IPO also secured Rs 8.52 crore from anchor investors, which typically signals institutional confidence and can support a positive listing outcome. However, investors should treat GMP cautiously: it is unofficial, unregulated and can shift substantially between the last subscription day and listing.

Avience Biomedicals: Business Model and Why the Diagnostics Sector Attracts IPO Investors

1. Molecular Diagnostics and IVD Manufacturer

Avience Biomedicals Limited, founded in 2019 and headquartered in Noida, Uttar Pradesh, is an ISO-certified manufacturer, supplier and exporter of molecular diagnostic solutions. The company started with rapid test kits (COVID-19, HIV, malaria, dengue, HBsAg, and related infectious disease diagnostics) and expanded to include serology products, biochemistry analysers, haematology analysers and molecular diagnostics. Avience Biomedicals operates its manufacturing facility in Noida and has also been allotted industrial land in the Medical Device Park at the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh, where it plans to set up a new manufacturing facility using IPO proceeds. The company serves pathology labs, microbiology labs, hospitals, research centres and government bodies across India and some overseas markets through B2B and B2G channels.

2. Mindray Channel Partnership

A notable strength of Avience Biomedicals is its channel partnership with Mindray, one of the world’s leading medical device companies. Through this partnership, Avience Biomedicals can offer Mindray biochemistry analysers and haematology equipment alongside its own manufactured diagnostic kits, creating a comprehensive product offering for hospital and laboratory clients. This partnership also provides Avience with access to Mindray’s service and training infrastructure, enhancing customer stickiness for the Avience Biomedicals IPO company’s client relationships.

Avience Biomedicals IPO Valuation and Risks

Kunal Singla cautions that the Avience Biomedicals IPO appears fully priced based on the most recent financial data, with the sharp revenue and profit growth in FY25 (revenue +88.6%, PAT +237.9%) partly reflecting post-pandemic diagnostic sector recovery. The sustainability of this growth rate into FY26 and FY27 will be a key question for investors who receive allotment and are considering a hold strategy. Customer concentration risk is significant: the top 10 customers contributed 56.82% of FY25 revenues. SME-specific liquidity risk also applies.

Conclusion

The Avience Biomedicals IPO GMP stands at Rs 85 on Day 3 of tracking, implying an expected listing price of approximately Rs 293 (+40.9% over Rs 208 upper band). The rising GMP trajectory and Rs 8.52 crore anchor investor participation are positive signals. The company is an ISO-certified molecular diagnostics manufacturer with FY25 revenue of Rs 45.97 crore (+88.6%) and PAT of Rs 7.23 crore (+237.9%). Consult a SEBI-registered financial advisor before investing in SME IPOs.

Disclaimer: This article is for educational and informational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Please read all scheme-related documents carefully before investing. Univest (Uniresearch Global Pvt Ltd) is a SEBI-registered Research Analyst (INH000013776). Past performance is not indicative of future returns.

Frequently Asked Questions

What is the Avience Biomedicals IPO GMP today?

Ans. The Avience Biomedicals IPO grey market premium (GMP) stands at Rs 85 on Day 3 of GMP tracking. This implies an expected listing price of approximately Rs 293, representing a potential gain of approximately 40.9% above the upper issue price of Rs 208. The GMP has risen progressively from Rs 40 in pre-subscription tracking to Rs 70 on Day 1 and Rs 85 on Day 3, indicating strengthening grey market demand.

What is the Avience Biomedicals IPO price band and lot size?

Ans. The Avience Biomedicals IPO price band is Rs 196 to Rs 208 per share (face value Rs 10 each). The lot size is 600 shares. Retail investors must apply for a minimum of 2 lots (1,200 shares), requiring an investment of Rs 2,49,600 at the upper price band of Rs 208. sNII investors must apply for a minimum of 3 lots (1,800 shares) at Rs 3,74,400.

What is Avience Biomedicals’ business?

Ans. Avience Biomedicals Limited is a Noida-based ISO-certified manufacturer, supplier and exporter of molecular diagnostic solutions. Its products include IVD rapid test kits for COVID-19, HIV, malaria, dengue and HBsAg, along with serology products, biochemistry analysers, haematology analysers and Viral Transport Media (VTM). It also serves as a channel partner for Mindray, distributing biochemistry and haematology equipment. Customers include pathology labs, hospitals, research centres and government bodies.

What are Avience Biomedicals’ financial results?

Ans. Avience Biomedicals reported FY25 revenue of Rs 45.97 crore, up approximately 88.6% from Rs 24.37 crore in FY24. Profit after tax grew approximately 237.9% to Rs 7.23 crore from Rs 2.14 crore in FY24. The company had 75 permanent and 33 contractual employees as of the most recent available data. Outstanding borrowings were approximately Rs 26.73 crore. The high revenue and profit growth partly reflects the diagnostic sector recovery trend.

What are Avience Biomedicals’ IPO risks?

Ans. Key risks include: customer concentration (top 10 customers contributed 56.82% of FY25 revenues); dependence on third-party suppliers for traded medical devices and raw materials; high borrowings of Rs 26.73 crore; operating history as a relatively young company founded in 2019; sustainability of the FY25 growth rate not guaranteed; and SME-specific liquidity risk post-listing. The issue also appears fully priced at current valuations per analyst commentary. Consult a SEBI-registered financial advisor.

What will Avience Biomedicals use IPO proceeds for?

Ans. Avience Biomedicals will use the Rs 30.24 crore fresh issue proceeds for: capital expenditure towards setting up a new manufacturing unit at YEIDA (Yamuna Expressway Industrial Development Authority) Medical Device Park, Uttar Pradesh; working capital requirements to support business operations; and general corporate purposes. The new manufacturing unit at the Medical Device Park will expand production capacity for diagnostic kits and medical devices.

What is the significance of the anchor investor participation?

Ans. Avience Biomedicals raised Rs 8.52 crore from anchor investors before the public subscription opened. Anchor investors are qualified institutional buyers (QIBs) who subscribe before the IPO opens and are subject to a mandatory lock-in period post-listing. Anchor investor participation is generally viewed as a positive signal, as it indicates institutional confidence in the company’s fundamentals and valuation. However, anchor participation does not guarantee listing gains or post-listing stock performance.

Should I apply for Avience Biomedicals IPO?

Ans. Whether to apply for Avience Biomedicals IPO depends on your assessment of the molecular diagnostics growth opportunity, the company’s ability to sustain FY25-level revenue growth, and your comfort with SME IPO risks. The GMP of Rs 85 implies strong grey market enthusiasm, and anchor investor participation adds a positive signal. However, the issue appears fully priced, customer concentration is high and the SME platform has lower liquidity. Consult a SEBI-registered financial advisor before applying.